Wire Stories

Category Added in a WPeMatico Campaign

Cullgen_logo_FINAL_4-21-2020_transparent_PNG

Cullgen Announces First-In-Human Dose in Phase I/II Trial of CG001419, a First-in-Class TRK Protein Degrader for Treatment of Cancer Patients

CG001419 is Cullgen’s first protein degrader to enter clinical development SAN DIEGO & SHANGHAI--(BUSINESS WIRE)--Cullgen Inc., a leading biotechnology company...